CareDx Appoints New CMO, Adds Directors

Ticker: CDNA · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1217234

Sentiment: neutral

Topics: leadership-change, board-of-directors, executive-appointment

Related Tickers: CDNA

TL;DR

CareDx shakes up leadership: new CMO, two directors join, one departs.

AI Summary

CareDx, Inc. announced on March 9, 2024, the appointment of Dr. Veronica S. Hipólito as Chief Medical Officer and the election of Dr. Hipólito and Dr. Robert L. Nussbaum to its Board of Directors. Additionally, the company disclosed that Dr. Hipólito will receive a base salary of $425,000 and equity awards as part of her compensation. The filing also noted the departure of Dr. John L. Reynolds from the Board of Directors.

Why It Matters

This filing indicates significant changes in CareDx's leadership, particularly in its medical and directorial roles, which could impact the company's strategic direction and medical affairs.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can signal strategic shifts or internal challenges, warranting closer observation.

Key Numbers

Key Players & Entities

FAQ

What is Dr. Veronica S. Hipólito's new role at CareDx?

Dr. Veronica S. Hipólito has been appointed as the Chief Medical Officer and elected to the Board of Directors of CareDx, Inc.

Who else was elected to the Board of Directors?

Dr. Robert L. Nussbaum was also elected to the Board of Directors of CareDx, Inc.

Who departed from the Board of Directors?

Dr. John L. Reynolds departed from the Board of Directors of CareDx, Inc.

What is Dr. Hipólito's annual base salary?

Dr. Hipólito's annual base salary is $425,000.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on March 9, 2024.

Filing Stats: 1,039 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2024-03-11 16:02:01

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 11, 2024 CAREDX, INC. By: /s/ Abhishek Jain Abhishek Jain Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing